EP1691783A1 — Pre-metered dry powder inhaler for moisture-sensitive medicaments
Assigned to Boehringer Ingelheim International GmbH · Expires 2006-08-23 · 20y expired
What this patent protects
The invention is directed to a pre-metered dry powder inhaler provided with a dry powder dose of tiotropium and excipient(s) loaded into a container comprising a dry, high barrier seal, which prevents ingress of moisture so that the fine particle structure of the powder dose is p…
USPTO Abstract
The invention is directed to a pre-metered dry powder inhaler provided with a dry powder dose of tiotropium and excipient(s) loaded into a container comprising a dry, high barrier seal, which prevents ingress of moisture so that the fine particle structure of the powder dose is preserved. The dry powder dose has been formed by either volumetric or electric field dose forming methods. The invention is also directed to a dry powder dose of tiotropium loaded into a container as described above. The dry powder inhaler and the dry powder dose of the invention is intended for use in the treatment of asthma and other respiratory disorders.
Drugs covered by this patent
- Arnuity Ellipta (FLUTICASONE FUROATE) · Haleon Us Holdings
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.